<DOC>
	<DOCNO>NCT00734058</DOCNO>
	<brief_summary>The purpose study conduct pivotal evaluation EndoPhotonix™ SOLAR™ System ATRILAZE™ System order obtain labeling claim device treatment atrial fibrillation . The study test safety effectiveness EndoPhotonix™ Laser Ablation Systems photocoagulate cardiac tissue cardiac surgery , create electrical isolation pulmonary vein create electrical isolation lesion order treat atrial fibrillation . The surgical procedure conduct concomitant mitral valve repair replacement surgery combination cardiac surgery include aortic valve surgery , tricuspid valve surgery , coronary artery bypass surgery .</brief_summary>
	<brief_title>SOLAR &amp; ATRILAZE Atrial Fibrillation Trial</brief_title>
	<detailed_description>The study objective generate Level II control data support expansion indication SOLAR™ System base 0-30 day data ; well support expansion indication SOLAR™ System ATRILAZE™ System treatment atrial fibrillation base 180 day data . The data evaluate compare post-operative data historical control data . The subject study cohort receive laser ablation therapy use investigational device concomitant surgical procedure .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Age least 18 year Documented long term persistent atrial fibrillation ( also know permanent AF ) .of least 3 month duration . Persistent AF define AF sustain beyond seven day , last less seven day necessitate pharmacologic electrical cardioversion . Long term persistent AF define continuous AF great three month duration . Concomitant indication open heart surgery least one following : Mitral valve repair replacement Aortic valve repair replacement Tricuspid valve repair replacement Atrial septal defect ( ASD ) repair Patent foramen ovale ( PFO ) closure Coronary artery bypass procedure Be able take anticoagulation therapy ( Warfarin / Coumadin® ) Be able fulfill study requirement Willing able comply requirement protocol include followup requirement Willing able sign study specific inform consent Life expectancy &lt; 1 year NYHA class = IV Left ventricular ejection fraction ( LVEF ) measurement &lt; 30 % Left atrial diameter &gt; 7.5 cm WolffParkinsonWhite ( WPW ) Syndrome Pregnancy desire pregnant within 1 year study treatment Myocardial infarction within previous 6 week Presence previously implant device ( valve , CS lead , ICD ) Known allergy , contraindication , inability comply warfarin ( Coumadin® ) heparin therapy Known allergy contraindication comply antiarrhythmic ( Class IA , IC , III ) therapy Previous thoracic procedure result sternal opening and/or pericardial opening ( e.g. , CABG , valve replacement repair ) Current diagnosis active endocarditis , local systemic infection Renal failure require dialysis hepatic failure Emergent cardiac surgery ( cardiogenic shock ) Preoperative need intraaortic balloon pump , IV inotropes vasoactive agent Currently participate another clinical research study Cerebral vascular accident transient ischemic attack within previous 180 day time document residual neurological deficit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Ablation</keyword>
	<keyword>AF</keyword>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Cardiac</keyword>
	<keyword>Endocardial</keyword>
	<keyword>Endocardium</keyword>
	<keyword>EP</keyword>
	<keyword>Electrophysiology</keyword>
	<keyword>Epicardial</keyword>
	<keyword>Epicardium</keyword>
	<keyword>Heart</keyword>
	<keyword>Interventional</keyword>
	<keyword>Lesion</keyword>
	<keyword>PVI</keyword>
	<keyword>Pulmonary Vein</keyword>
	<keyword>MAZE</keyword>
	<keyword>Surgery</keyword>
	<keyword>Surgical</keyword>
	<keyword>Treatment</keyword>
	<keyword>Patients persistent AF 3 month duration</keyword>
	<keyword>Requiring concomitant open heart surgery</keyword>
</DOC>